Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
N

NextBioMedical Co Ltd
KOSDAQ:389650

Watchlist Manager
NextBioMedical Co Ltd
KOSDAQ:389650
Watchlist
Price: 73 900 KRW 2.92% Market Closed
Market Cap: ₩606B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
NextBioMedical Co Ltd

Wall Street analysts forecast NextBioMedical Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NextBioMedical Co Ltd is 99 280 KRW with a low forecast of 83 830 KRW and a high forecast of 126 000 KRW.

Lowest Forecast
Wall Street Target
83 830 KRW
13% Upside
Average Forecast
Wall Street Target
99 280 KRW
34% Upside
Highest Forecast
Wall Street Target
126 000 KRW
71% Upside
Lowest
Price Target
83 830 KRW
13% Upside
Average
Price Target
99 280 KRW
34% Upside
Highest
Price Target
126 000 KRW
71% Upside
NextBioMedical Co Ltd Competitors:
Price Targets

Revenue
Forecast

95% / Year
Past Growth
66% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
95% / Year
Past Growth
66% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 1 year the compound annual growth rate for NextBioMedical Co Ltd's revenue is 95%. The projected CAGR for the next 3 years is 66%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
63% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
63% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

The compound annual growth rate of NextBioMedical Co Ltd's net income for the next 3 years is 63%.

What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NextBioMedical Co Ltd's stock price target?
Price Target
99 280 KRW

According to Wall Street analysts, the average 1-year price target for NextBioMedical Co Ltd is 99 280 KRW with a low forecast of 83 830 KRW and a high forecast of 126 000 KRW.

What is NextBioMedical Co Ltd's Revenue forecast?
Projected CAGR
66%

For the last 1 year the compound annual growth rate for NextBioMedical Co Ltd's revenue is 95%. The projected CAGR for the next 3 years is 66%.

What is NextBioMedical Co Ltd's Net Income forecast?
Projected CAGR
63%

The compound annual growth rate of NextBioMedical Co Ltd's net income for the next 3 years is 63%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 319,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.